MDT-AP-0604
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 35.04
- os_event
- false
- age_years
- 13
- sex
- F
- new_clusters
- C3
- umap1_2d
- 5.793611147
- umap2_2d
- 3.667057509
- umap1_3d
- 2.829782835
- umap2_3d
- -2.669855522
- umap3_3d
- -2.892058892
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- UNFOLDED_PROTEIN_RESPONSE+0.330
- DNA_REPAIR+0.260
- MITOTIC_SPINDLE+0.250
- PI3K_AKT_MTOR_SIGNALING+0.250
- ADIPOGENESIS+0.120
- HEME_METABOLISM+0.120
- WNT_BETA_CATENIN_SIGNALING+0.100
- PROTEIN_SECRETION+0.090
- P53_PATHWAY+0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.460
- ANGIOGENESIS-0.390
- IL6_JAK_STAT3_SIGNALING-0.390
- ALLOGRAFT_REJECTION-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- ANDROGEN_RESPONSE-0.350
- COAGULATION-0.350
- INFLAMMATORY_RESPONSE-0.320
- COMPLEMENT-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208948 | — | — | 0.869 |
| 2 | MDT-AP-0574 | Med | Medulloblastoma | 0.866 |
| 3 | SRR663681 | GTEX | — | 0.858 |
| 4 | SRR1327975 | GTEX | — | 0.852 |
| 5 | SRR1403915 | GTEX | — | 0.850 |
| 6 | SRR1387072 | GTEX | — | 0.847 |
| 7 | SRR1410934 | GTEX | — | 0.845 |
| 8 | SRR1447986 | GTEX | — | 0.845 |
| 9 | SRR1317323 | GTEX | — | 0.840 |
| 10 | SRR1441141 | GTEX | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |